NCT03545438View on ClinicalTrials.gov

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

May 30, 2018

Study Completion Date

June 30, 2018

Conditions
Hypercholesterolemia
Interventions
BIOLOGICAL

LIB003

LIB003 or placebo

Trial Locations (1)

45227

Medpace (MARC/CPU), Cincinnati

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

LIB Therapeutics LLC

INDUSTRY

NCT03545438 - Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003 | Biotech Hunter | Biotech Hunter